Targeted Oncology™ announces first recipient of 2024 for its Oncology Icons award program
23 avr. 2024 10h46 HE
|
Targeted Oncology™
CRANBURY, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
09 avr. 2024 12h00 HE
|
Immuneering Corporation
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
27 mars 2024 08h00 HE
|
Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
14 mars 2024 07h00 HE
|
Immuneering Corporation
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for...
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
05 mars 2024 17h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
04 mars 2024 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
20 févr. 2024 08h00 HE
|
Immuneering Corporation
– Fast Track designation has the potential to accelerate lead asset IMM-1-104’s path to U.S. FDA submission for pancreatic ductal adenocarcinoma – – Company expects multiple readouts from its Phase...
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
12 déc. 2023 08h00 HE
|
Immuneering Corporation
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Targeted Oncology™ announces recipients of its Oncology Icons award program
15 nov. 2023 14h10 HE
|
Targeted Oncology™
CRANBURY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
03 août 2023 16h05 HE
|
Immuneering Corporation
- Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) annual meeting, with IMM-1-104 demonstrating Cmax, half-life, and...